Brentuximab vedotin: An anti-CD30 antibody-drug conjugate

American Journal of Health-System Pharmacy

Volumn 70, Issue 7, 2013, Pages 589-597

  Bradley, Amber M ^a   Devine, Meghan ^b   Deremer, David ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Georgia Health Sciences Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTIBODY CONJUGATE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETOCONAZOLE; NAVELBINE; PREDNISONE; RIFAMPICIN; VINBLASTINE; VINCRISTINE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LUNG DISEASE; LUNG EMBOLISM; MOTOR NEUROPATHY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATITIS; REED STERNBERG CELL; REVIEW; SALVAGE THERAPY; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 84875446702     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110608     Document Type: Review

References (66)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hodgkin lymphoma. Version 2.2011. www.nccn.org/professionals/ physician-gls/pdf/hodgkins.pdf(accessed 2011 Oct 3).
2. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
3. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:497-506.
4. Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol. 2010; 79:1544-52.
5. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011; 117:4208-17.
6. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000; 18:2615-9. (Pubitemid 30432529)
7. Deutsch YE, Tadmor T, Podack ER et al. CD30: an important new target in hematologic malignancies. Leuk Lymphoma. 2011; 52:1641-54.
8. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341:1051-4. (Pubitemid 23114397)
9. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359:2065-71. (Pubitemid 34680969)
10. Sureda A, Constans M, Iriondo A et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005; 16:625-33. (Pubitemid 40613330)
11. Adcetris (brentuximab vedotin) package insert. Bothell, WA: Seattle Genetics; 2011 Aug.
12. Foyil KV, Bartlett NL. Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep. 2010; 5:140-7.
13. Stein H, Foss HD, Durkop H et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood. 2000; 96:3681-95.
14. Savage KJ, Harris NL, Vose JM et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ sALCL and peripheral T-cell lymphoma, not otherwise specified: a report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 111:5496-504.
15. Gruss HJ, Ulrich D, Dower SK et al. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-κβtranscription factor. Blood. 1996; 87:2443-9. (Pubitemid 26086888)
16. Forero-Torres A, Leonard JP, Younes A et al. A phase II study of SGN-30 (anti- CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009; 146:171-9.
17. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010; 14:529-37.
18. Fransisco JS, Cerveny CG, Meyer DL et al. cAC10-vmMMAE, an anti-CD30- monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003; 102:1458-65. (Pubitemid 36988057)
19. Cerveny CG, Law CL, McCormick RS et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia. 2005; 19:1648-55. (Pubitemid 43090411)
20. Okeley NM, Miyamoto JB, Zhang X et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010; 16:888-97.
21. Seattle Genetics. Seattle Genetics presents data on antibody-drug conjugate programs at AACR. www.seattlegenetics.com (accessed 2011 Oct 19).
22. Sanderson RJ, Hering MA, James SF et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005; 11:843-52. (Pubitemid 40116913)
23. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363:1812-21.
24. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25:579-86. (Pubitemid 350002966)
25. Fanale MA, Forero-Torres A, Rosenblatt JD et al. A phase 1 weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012; 18:248-55.
26. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30:2183-9.
27. Shustov AR, Advani R, Brice P et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2010; 116:961. Abstract.
28. Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30:2190-6.
29. Advani RH, Shustov AR, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: a phase 2 study update. Blood. 2011; 118:443. Abstract.
30. Illidge T, Bouabdallah R, Chen RW et al. Allogeneic transplant following brentuximab vedotin treatment in patients with relapsed or refractory CD30+ lymphomas. Blood. 2011; 118:3091. Abstract.
31. Chen RW, Forman SJ, Palmer J et al. Brentuximab vedotin (SGN-35) enables successful reduced intensity hematopoietic cell transplantation in relapsed/refractory Hodgkin lymphoma. Blood. 2011; 118:664. Abstract.
32. Chen R, Palmer JM, Thomas SH et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012; 119:6379-81.
33. Gopal AK, Ramchandren R, O'Connor OA et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012; 120:560-8.
34. Oncology Drug Advisory Committee (ODAC) briefing document: brentuximab vedotin (SGN-35). www.fda.gov/downloads/AdvisoryCommittees/.../Drugs/.../ UCM262598.pdf (accessed 2011 Oct 18).
35. ClinicalTrials.gov. A phase 3 study of brentuximab vedotin (SGN-35) in patients at high risk of residual Hodgkin lymphoma following stem cell transplant (the AETHERA trial). http://clinicaltrials.gov/ct2/show/NCT01100502? term=NCT01100502&rank=1 (accessed 2011 Sep 30).
36. ClinicalTrials.gov. Brentuximab vedotin before autologous stem cell transplant in treating patients with Hodgkin lymphoma. http://clinicaltrials. gov/ct2/show/NCT01393717?term=NCT01393717&rank=1 (accessed 2011 Sep 30).
37. Oflazoglu E, Kissler KM, Sievers EL et al. Combination of the anti-CD-d 30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumor activity in Hodgkin lymphoma. Br J Haematol. 2008; 142:69-73. (Pubitemid 351783148)
38. ClinicalTrials.gov. A phase 1 study of brentuximab vedotin combined with ABVD for Hodgkin lymphoma. http://clinicaltrials.gov/ct2/show/NCT01060904?term= NCT01060904&rank=1(accessed 2011 Sep 30).
39. Younes A, Connors JM, Park SI et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. Blood. 2011; 118:955. Abstract.
40. MedWatch. Adcetris (brentuximab vedotin): drug safety communication- progressive multi focal leukoencephalopathy and pulmonary toxicity. www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm287710.htm (accessed 2012 Jan 23).
41. ClinicalTrials.gov. A phase 1 study of brentuximab vedotin given sequentially and combined with multi-agent chemotherapy for aCD30-positive mature T-cell and NK-cell neoplasms. http://clinicaltrials.gov/ct2/show/ NCT01309789?term=NCT01309789&rank=1 (accessed 2011 Sep 30).
42. ClinicalTrials.gov. A study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma. http://clinicaltrials.gov/ct2/ show/NCT01421667?term=NCT01421667&rank=1 (accessed 2011 Sep 30).
43. ClinicalTrials.gov. SGN-35 in CD30- positive lymphoproliferative disorders (ALCL), mycosis fungoides (MF), and extensive lymphomatoid papulosis (LyP). http://clinicaltrials.gov/ct2/show/NCT01352520?term=NCT01352520&rank= 1(accessed 2011 Sep 30).
44. Forero-Torres A, Berryman RB, Advani RH et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (Hodgkin lymphoma) or systemic anaplastic large cell lymphoma (sALCL). Blood. 2011; 118:3711. Abstract.
45. Chen R, Gopal AK, Smith SE et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2010; 116:283. Abstract.
46. Moskowitz AJ, Perales MA, Kealramani T et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009; 146:158-63.
47. Thompson KJ, Peggs KS, Blundell E et al. A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft. Leuk Lymphoma. 2007; 48:847-8.
48. Lin TS, Avalos BR, Penza SL et al. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant. 2002; 29:763-7. (Pubitemid 34618908)
49. Sarina B, Castagna L, Farina L et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of Hodgkin lymphomaA typing and donor availability. Blood. 2010; 115:3671-7.
50. Aurer I, Radman I, Nemet D et al. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie. 2005; 28:567-71. (Pubitemid 41513142)
51. Zinzani PL, Bendandi M, Stefoni V et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica. 2000; 85:926-9.
52. Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol. 1994; 5:817-20. (Pubitemid 24341874)
53. Rule S, Tighe M, Davies S et al. Vinorelbine in the treatment of lymphoma. Hematol Oncol. 1998; 16:101-5. (Pubitemid 29202168)
54. Venkatesh H, Di Bella N, Flynn TP et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma. 2004; 5:110-5. (Pubitemid 39378321)
55. Little R, Wittes RE, Longo DL et al. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol. 1998; 16:584-8. (Pubitemid 28135603)
56. Thomas J, de Pauw B, Hagenbeek A et al. Phase II study of cytarabine in Hodgkin's disease. Eur J Cancer. 1992; 28A:857-9.
57. Younes A, Cabanillas F, McLaughlin PW et al. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Ann Oncol. 1996; 7:1083-5. (Pubitemid 27050835)
58. Food and Drug Administration. Adcetris: brentuximab vedotin CD30- directed therapy for systemic anaplastic large cell lymphoma. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM267033.pdf (accessed 2011 Oct 17).
59. O'Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29:1182-9.
60. Coiffer B, Pro B, Prince M et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. Presented at ASH Annual Meeting. Orlando, FL; 2010 Dec 5.
61. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001; 113:185-7. (Pubitemid 32423320)
62. Czuczman MS, Porcu P, Johnson J et al. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and periph Am J Health-Syst Pharm-Vol 70 Apr 1, 2013 597 eral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007; 48:97-103. (Pubitemid 46978628)
63. ClinicalTrials.gov. An SGN-35 trial for patients who have previously participated in an SGN-35 study. http://clinicaltrials.gov/show/NCT00947856 (accessed 2012 Dec 18).
64. ClinicalTrials.gov. A randomized, openlabel, phase 3 trial of brentuximab vedotin(SGN-35) versus physician's choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. http://clinicaltrials. gov/ct2/show/NCT01578499?term=NCT01578499&rank=1 (accessed 2013 Feb 11).
65. ClinicalTrials.gov. A randomized, doubleblind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas. http://clinicaltrials.gov/ct2/show/NCT01777152?term=NCT01777152&rank=1 (accessed 2013 Feb 11).
66. ClinicalTrials.gov. A randomized, openlabel, phase 3 trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma. http://clinicaltrials.gov/ct2/show/NCT01712490?term= NCT01712490&rank=1 (accessed 2013 Feb 11).